X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
PLETHICO PHARMACEUTICALS LTD. Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

PLETHICO PHARMACEUTICALS LTD.  (PLPL)


Here is the latest financial fact sheet of PLETHICO PHARMA. For more details, see the PLETHICO PHARMA quarterly results and PLETHICO PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
plethico pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 7.9       No. of shares m 34.07
    Mkt Cap Rs m 271       % ch % -4.9
    Vol '000 10.4       % ch week % -4.9
    P/E X -1.1       % ch 1-mth % -5.6
    P/CF X 0.2       % ch 12-mth % -70.2
    EPS (TTM) Rs -7.1       52 week H/L Rs 36.9/7.6
(As on Jun 13, 2016 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Dec-09
*
12
Dec-10
*
12
Dec-11
*
12
Dec-12
*
15
Mar-14
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs380450395397395 
Low Rs8131233115631 
Sales per share (Unadj.) Rs367.9451.7456.9478.7604.4 
Earnings per share (Unadj.) Rs63.771.730.229.832.5 
Diluted earnings per shareRs63.771.730.229.832.5 
Cash flow per share (Unadj.) Rs68.579.535.435.051.3 
Dividends per share (Unadj.) Rs2.502.50000 
Adj. dividends per shareRs2.502.500.000.000.00 
Dividend yield (eoy) %1.10.7000 
Book value per share (Unadj.) Rs259.7313.4400.5401.1473.6 
Adj. book value per shareRs259.7313.5400.6401.2473.7 
Shares outstanding (eoy) m34.0834.0834.0834.0834.08 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.60.80.80.60.4 
Avg P/E ratio x3.65.312.09.36.6 
P/CF ratio (eoy) x3.44.810.37.94.2 
Price / Book Value ratio x0.91.20.90.70.5 
Dividend payout %3.93.5000 
Avg Mkt Cap Rs m7,85512,98412,3719,4287,262 
No. of employees `000NANANANANA 
Total wages/salary Rs m1,1011,1731,1891,1891,596 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
  INCOME DATA
Net Sales Rs m12,53815,39315,57016,31520,598 
Other income Rs m-52-201843305386 
Total revenues Rs m12,48515,19316,41416,62020,984 
Gross profit Rs m2,4593,3262,1101,5802,818 
Depreciation Rs m166264176177642 
Interest Rs m3013068356141,593 
Profit before tax Rs m1,9402,5551,9421,093969 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m164137-63000 
Tax Rs m-6624828378-138 
Profit after tax Rs m2,1692,4441,0291,0151,107 
Gross profit margin %19.621.613.69.713.7 
Effective tax rate %-3.49.714.67.1-14.3 
Net profit margin %17.315.96.66.25.4 
  BALANCE SHEET DATA
Current assets Rs m7,4289,38115,00717,00918,877 
Current liabilities Rs m1,4312,1828,60110,96311,896 
Net working cap to sales %47.846.841.137.133.9 
Current ratio x5.24.31.71.61.6 
Inventory Days Days4037434236 
Debtors Days Days132151228274198 
Net fixed assets Rs m6,1456,6648,4648,2219,861 
Share capital Rs m341341341341341 
"Free" reserves Rs m8,16410,24111,10511,22412,331 
Net worth Rs m8,84910,68213,64913,67016,139 
Long term debt Rs m5,5775,4283,1932,5594,706 
Total assets Rs m15,56118,03425,59527,31733,146 
Interest coverage x7.59.43.32.81.6 
Debt to equity ratio x0.60.50.20.20.3 
Sales to assets ratio x0.80.90.60.60.6 
Return on assets %15.915.27.36.08.1 
Return on equity %24.522.97.57.46.9 
Return on capital %16.718.612.810.512.3 
Exports to sales %24.617.017.619.521.4 
Imports to sales %4.11.16.214.115.2 
Exports (fob) Rs m3,0852,6242,7453,1754,402 
Imports (cif) Rs m5171699602,3063,136 
Fx inflow Rs m3,0852,6242,7453,1754,402 
Fx outflow Rs m7963031,0892,3643,184 
Net fx Rs m2,2892,3201,6568111,219 
  CASH FLOW
From Operations Rs m 1,654 1,764 -2,717 -610 2,437 
From Investments Rs m -335 -847 -997 75 -6,265 
From Financial Activity Rs m -1,232 -853 3,567 -405 2,490 
Net Cashflow Rs m 88 64 -147 -940 -1,337 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for plethico pharmaceuticals ltd.

 Share Holding
Indian Promoters : 82.7%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 4.3%
FIIs : 5.5%
ADR/GDR : 0.0%
Free float : 7.5%
Shareholders : 10,665
Pledged promoter(s) holding : 85.7%
 Company Information
Top
    REGD OFF: A B Road, Manglia, Indore, Madhya Pradesh - 453 771
    E-MAIL: companysecretary@plethico.com     WEB: www.plethico.com
    TELEPHONE: (0731) 242 2881     FAX: (0731) 242 093
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
    AUDITOR: N. P. Gandhi & Co.
CHM: Shashikant Patel (MD) COMP SEC: Amrish Kumar Chourasia YEAR OF INC: 1991 BSE CODE: 532739 FV (Rs): 10 DIV YIELD (%): -

More pharmaceuticals Company Fact Sheets:   DIVIS LABORATORIESBIOCON LTDWOCKHARDT LTD.FRESENIUS KABI ONCO.AUROBINDO PHARMA


Today's Market

Sensex Remains Firm; Energy Stocks Lead Gains(01:30 pm)

After opening the day on a positive note, share markets in India have continued the momentum and are trading marginally above the dotted line. Sectoral indices are trading on a positive note with stocks in the oil and gas sector.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

As Digital Transactions Fall, Indians Are Going Back to Cash(Vivek Kaul's Diary)

Mar 16, 2017

Digital transactions have fallen since December 2016 both in value and volume terms.

Stock Markets and Gold Rally, Dollar Tumbles(Chart Of The Day)

Mar 16, 2017

Markets are moving up even after the fed interest rate hike.

Why You Should Try SCOREFASTTM Right Now(Daily Profit Hunter)

Mar 10, 2017

Asad Dossani discusses why SCOREFASTM will be a successful trading strategy

4 Things To Watch Out For After Modi's Landslide Win In UP Polls(Outside View)

Mar 15, 2017

PersonalFN explains why you need to wary while investing in equities despite Modi's UP win.

More

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE PLETHICO PHARMA WITH

MARKET STATS